. A panel of 21 monoclonal antibodies (11 anti-N1, 2 anti-N2, and 8 anti-BNA) was assembled from materials provided by our collaborators at Mt. Sinai School of Medicine as well as commercial sources. Each antibody was "printed" in replicates of three on a VaxArray screening array. The anti-N1 and N2 antibodies were printed on one lot of slides and the anti-BNA antibodies were printed on another. Each slide lot had its corresponding array printed in 16 wells on a modified glass substrate using the same parameters utilized for the other VaxArray technologies. To evaluate mAbs for specificity and coverage, a test panel of 12 influenza A antigens, 3 influenza B antigens, and 3 seasonal trivalent influenza vaccines (TIVs) were diluted to 3 µg/mL HA (NA concentrations were unknown) and added individually to the N1/N2 array. A panel of 2 influenza B antigens, 4 influenza A antigens, and 3
TIVS were diluted to 3 µg/mL HA and added to the BNA array. Cross-reactivity was also evaluated by adding the B antigens to the "A microarray" and vice versa. Each well was labeled with a polyclonal antibody label (InDevR, Cat # VXI-7601). The resulting fluorescent signal from each antibody "spot" within the array was measured by the VaxArray Imaging System (InDevR, Cat # VX-6000) and the raw intensity values were averaged for each capture mAb. The resulting average relative fluorescent units were compared for each antigen on each capture mAb and summarized in Supplementary Figure 1ab . As shown in the Supplementary Figure 1a , anti-N1 mAbs 2, 6, and 8 demonstrated some levels of cross-reactivity, interacting with H3N2 antigens. None of the anti-N1 and anti-N2 mAbs reacted with B antigens. Of the anti-N1 mAbs, 4 and 11 demonstrated 100% coverage (detecting all strains tested within the N1 subtype) and 100% specificity (not detecting any non-N1 samples). Anti-N2 mAbs, 12 and 13, and anti-BNA, mAbs 20 and 21, also demonstrated 100% coverage and specificity.
The antibodies downselected for coverage and specificity were assessed for stability indication capabilities.
References antigens representing H1N1, H3N2, and BV subtypes were analyzed in triplicate (n=3) by VXI-sNA before (T0) and after 20 hours incubated at 45°C (T20). %T0 values for each sample (average signal at T20 divided by average signal at T0) were calculated. As demonstrated in Supplementary Figure 2 , all antibodies reported reductions in signal intensities of 37 -97% upon heat degradation, suggesting the downselected mAbs only bind properly folded NA and not degraded protein. VXI-sNA detects NA and not HA. Because NA is often at much lower concentrations than HA in vaccine formulations, we wanted to demonstrate that VXI-sNA was only quantifying NA and not affected by the much higher concentrations of HA in vaccines. To this end, recombinant H1, H3, B-Yamagata-like and B-Victoria-like HA proteins and a quadrivalent mixture of the four proteins were analyzed on VXI-sNA and the VaxArray Influenza Seasonal HA assay (Supplementary Figure 3ab) . The VaxArray HA assay was able to detect the recombinant HA proteins with robust signal. In contrast, the same recombinant HA formulations were not detected by the VaxArray NA assay, as expected. The signal intensities for each NA capture mAb was below the limit of quantification for the assay, suggesting that VXI-sNA is specific for NA and not affected by the presence of high concentrations of HA. 
Supplementary

SUPPLEMENTARY METHODS
Antibody Screening for Down-Selection of VXI-sNA Capture Antibodies. Monoclonal antibodies were printed in triplicate in 16 replicate arrays on a microarray slide (Fig. 2a) . Antigens were lysed in PBS + 1% Zwittergent 3-14 for 30 minutes and further diluted to 3 µg/mL of HA in PBB + 1% Zwittergent 3-14, before analysis using the standard VaxArray procedure described above. Each antigen was labeled with a "universal" neuraminidase-reactive polyclonal label antibody (NA A&B pAb Label, Cat # VXI-7616, InDevR). Coverage for a given antibody is defined as the number of subtype/type specific detection events (greater than 3x background signal intensity) divided by the number of subtype/type specific antigens evaluated against the antibody. Specificity for a given antibody is defined as the number of subtype/type specific detection events divided by the total number of detection events of the antibody.
Determination of Antibody Stability Indication Capabilities
